Merck KGaA, Darmstadt, Germany has announced that it has signed a definitive agreement to purchase Exelead (Indianapolis), a biopharma contract development and manufacturing organization (CDMO). Not to be confused with the similarly named Merck & Co., the German company will pay roughly $780 million in the acquisition. Exelead specializes in creating lipid nanoparticle and pegylated…
Exelead makes first precursor batch of Pfizer-BioNTech COVID-19 vaccine
Pharma industry contract manufacturer Exelead recently announced that it has delivered its first precursor batch of Prizer-BioNTech’s COVID-19 vaccine, produced at its recently expanded facility in Indianapolis. Exelead plans to add 50 jobs to help it meet COVID-19 vaccine demand. “We are extremely proud to be part of the manufacture of the Pfizer-BioNTech COVID-19 vaccine,…